LLY Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Unlocking Growth, Navigating Financial Triumphs And Market Expansion In The Pharmaceutical Arena
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$902.71 |
| 52 Week High | US$972.53 |
| 52 Week Low | US$516.57 |
| Beta | 0.42 |
| 11 Month Change | 6.79% |
| 3 Month Change | 6.20% |
| 1 Year Change | 53.93% |
| 33 Year Change | 276.91% |
| 5 Year Change | 714.06% |
| Change since IPO | 32,040.99% |
Recent News & Updates
Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside
Sep 04Eli Lilly: Tirzepatide's Winning Streak Continues
Aug 20Recent updates
Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside
Sep 04Eli Lilly: Tirzepatide's Winning Streak Continues
Aug 20Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)
Aug 12Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic
Aug 04Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China
Jul 25A Look At The Fair Value Of Eli Lilly and Company (NYSE:LLY)
Jul 16
Wall Street Lunch: Merger Monday In All Its Glory
Jul 085 Reasons Eli Lilly Just Keeps Rising
Jun 30Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis)
Jun 24Eli Lilly And Alzheimer's Disease: The Paucity Of Progress
Jun 17Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval
Jun 11These 4 Measures Indicate That Eli Lilly (NYSE:LLY) Is Using Debt Reasonably Well
Jun 10Eli Lilly's Growth And Challenges: A Cautious Buy
Jun 01Eli Lilly: Addressing Supply Challenges Should Accelerate Growth
May 26Eli Lilly: Bloated Stock
May 01What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S
Apr 22Wall Street Lunch: Lilly In Limelight
Apr 17Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets
Mar 29Shareholder Returns
| LLY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.0% | -3.1% | -4.4% |
| 1Y | 53.9% | 16.1% | 19.1% |
Return vs Industry: LLY exceeded the US Pharmaceuticals industry which returned 16.1% over the past year.
Return vs Market: LLY exceeded the US Market which returned 19.1% over the past year.
Price Volatility
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LLY has not had significant price volatility in the past 3 months.
Volatility Over Time: LLY's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| LLY fundamental statistics | |
|---|---|
| Market cap | US$812.82b |
| Earnings (TTM) | US$7.34b |
| Revenue (TTM) | US$38.92b |
110.7x
P/E Ratio20.9x
P/S RatioIs LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLY income statement (TTM) | |
|---|---|
| Revenue | US$38.92b |
| Cost of Revenue | US$7.49b |
| Gross Profit | US$31.43b |
| Other Expenses | US$24.09b |
| Earnings | US$7.34b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
| Earnings per share (EPS) | 8.15 |
| Gross Margin | 80.75% |
| Net Profit Margin | 18.86% |
| Debt/Equity Ratio | 212.9% |
How did LLY perform over the long term?
See historical performance and comparison